. Author manuscript; available in PMC: 2015 Mar 1.

Published in final edited form as: Leuk Lymphoma. 2013 Aug 13;55(3):624–627. doi: 10.3109/10428194.2013.820293

Table 1.

Acute Lymphoblastic Leukemia: patient Characteristics and in surface CD30 expression by flow cytometry immunophenotypic analysis

	T-ALL (n=34)	B-ALL (n=44)	p
Age, median(range), years	36(6–72)	47(4–85)
Gender, male/female	26/8	24/20
Lymphoblasts, median (range)(%)
• By morphology	61(3–97)	86(2–99)
• By flow cytometry	52(2–98)	52(2–92)
CD30 expression in all cases,
median (range)(%)	3.3 (0.1–86.8)	2.6 (0.0–68.8)	NS
Patients with ≥20%CD30 expression	13 (38%)	6 (14%)	0.017
• CD30+ blasts %, median (range)	40.0(22.7–86.8)	39.1(24.9–68.8)	NS
• MFI ratio	3.3 (1.8–37.9)	4.9 (3.0–8.8)	NS
CD30 expression by a 20% cutoff according to disease status and cytogenetics
Untreated patients	0/3 (0%)	1/12 (8%)	^* NS
Relapsed/persistent patient	13/31(42%)	5/32 (16%)	^* NS
Patients with a normal karyotype	4/15 (27%)	2/13 (15%)	^* NS
Patients with an abnormal karyotype	9/19 (47%)	4/31(13%)	^* NS
Patients with BCR-ABL1	1/2 (50%)	3/14 (21%)	^* NS
Patients without BCR-ABL1	12/32 (38%)	3/30 (10%)	^* NS

ALL: acute lymphoblastic leukemia. MFI: Mean fluorescence intensity;

NS: not significant. Comparisons were performed between B-ALL and T-ALL; within B-ALL and T-ALL subgroups; or combining B-ALL and T-ALL by disease status and cytogenetic data, calculated by the expression percentage or number of positive cases.